Beyond Air, Inc.
XAIRHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeBeyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. Valued at $2.1M, XAIR is a micro-cap name in its sector. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments.
Market Cap
$2.1M
Beta
0.21
P/E (TTM)
—
P/E (Fwd)
-1.26
EPS (TTM)
$-64.40
EPS (Fwd)
$-1.66
ROE
-519.5%
ROA
-57.5%
Cash
$9.8M
Total Debt
$23.6M
Free CF
-$14.1M
52W Change
-95.0%
Annual Financials
Cash vs Debt
Where XAIR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, XAIR finished 72.16% below its 150-day moving average ($7.65) and 81.27% below its 200-day moving average ($11.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XAIR overbought or oversold?
At the October 20, 2026 close, XAIR's RSI(14) was 25.4, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $9.8M in cash, though total debt stands at $23.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$14.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -519.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
XAIR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing XAIR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.